Detail

CHEPLAPHARM acquires product rights for ANEXATE® from F. Hofmann-La Roche

Amount of investment in the mid, double-digit million euro range. CHEPLAPHARM creates eight new jobs with this acquisition.

 

Amount of investment in the mid, double-digit million euro range. CHEPLAPHARM creates eight new jobs with this acquisition.

At the beginning of 2016, the high-growth pharmaceutical company CHEPLAPHARM Arzneimittel GmbH has secured the product rights for ANEXATE®, a benzodiazepine antagonist with the active agent Flumanzenil. As an antidote for drugs of the benzodiazepine group, it is typically used to counteract benzodiazepine sedation/overdose.

Neither party has disclosed the precise details of the purchase agreement, although a double-digit million EURO revenue is expected at the end of the year with this acquisition.

In 2012, CHEPLAPHARM has already acquired the rights for ROHYPNOL®, a benzodiazepine with the active ingredient Flunitrazepam. From a medical viewpoint, the benzodiazepine antidote ANEXATE® represents an ideal addition in this context, thereby perfectly complementing CHEPLAPHARM’s niche portfolio.

This acquisition is yet another part in its successful Buy-And-Build strategy. The management board commented on the acquisition as follows: "We are hoping to gain a foothold in those countries where ROHYPNOL® is sold, but where ANEXATE® is not yet approved. We would also like to make use of and expand the future potential of ANEXATE® with targeted collaboration focused on success with our global distribution partners, especially in regions where sales are weak. The 'Made in Europe' feature, associated with high quality, will help us significantly in this regard."

The major pharmaceutical company F. Hoffmann-La Roche has built up a prestigious image over the course of many decades. In many countries, ANEXATE® is a market leader. The main sales channels are clinics in more than 100 countries. This acquisition could raise the current export share of 80 percent to 85 to 90 percent by taking advantage of expansion potential. This means that CHEPLAPHARM is ideally diversified in its country and product mix and is therefore firmly on course towards becoming an internationally active "specialty pharmaceutical" company.

CHEPLAPHARM is planning to invest a total of 90 million euro (without funding applications) and to recruit 15 highly-qualified employees this year. Eight jobs were created at the Greifswald site from the ANEXATE® acquisition alone. With a total headcount of 90 and an annual turnover of 100 million euro (including subsidiaries) in 2015, CHEPLAPHARM is one of the fastest growing companies in the Mecklenburg-Western Pomerania region of Germany.

 


CHEPLAPHARM Arzneimittel GmbH was founded in 1998, with its company headquarters situated in Greifswald since the end of 2014. Its subsidiaries are based in Hamburg and Englewood in New Jersey, USA (15 miles from New York).

With a team of experienced experts, CHEPLAPHARM’s aim is to offer high-quality medications, dietary supplements, and cosmetics on the market. These products are manufactured under state-of-the-art conditions and strict quality control. CHEPLAPHARM sees itself as a provider of specialty pharma. The focus lies on active ingredient markets and clinical pictures that are too small for pharma corporate groups and generic producers. It is thus possible for CHEPLAPHARM to offer customers highly individual products. In many pharmaceutical forms and active ingredient markets, CHEPLAPHARM has a unique position.

CHEPLAPHARM holds more than 150 authorisations in more than 100 countries worldwide and has extensive experience in collaborating with our global distribution and marketing partners. Currently, CHEPLAPHARM employs 90 highly qualified staff members and, together with its subsidiaries, generates an annual turnover of 100 million euros.

 

Press office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com


*m/w/d
Zurück